These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 16428552

  • 1. A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model.
    Sycha T, Samal D, Chizh B, Lehr S, Gustorff B, Schnider P, Auff E.
    Anesth Analg; 2006 Feb; 102(2):509-16. PubMed ID: 16428552
    [Abstract] [Full Text] [Related]

  • 2. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin.
    Gazerani P, Pedersen NS, Staahl C, Drewes AM, Arendt-Nielsen L.
    Pain; 2009 Jan; 141(1-2):60-9. PubMed ID: 19004549
    [Abstract] [Full Text] [Related]

  • 3. Botulinum Toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin.
    Krämer HH, Angerer C, Erbguth F, Schmelz M, Birklein F.
    J Neurol; 2003 Feb; 250(2):188-93. PubMed ID: 12574949
    [Abstract] [Full Text] [Related]

  • 4. Botulinum toxin A does not alter capsaicin-induced pain perception in human skin.
    Schulte-Mattler WJ, Opatz O, Blersch W, May A, Bigalke H, Wohlfahrt K.
    J Neurol Sci; 2007 Sep 15; 260(1-2):38-42. PubMed ID: 17481662
    [Abstract] [Full Text] [Related]

  • 5. Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin.
    Tugnoli V, Capone JG, Eleopra R, Quatrale R, Sensi M, Gastaldo E, Tola MR, Geppetti P.
    Pain; 2007 Jul 15; 130(1-2):76-83. PubMed ID: 17194546
    [Abstract] [Full Text] [Related]

  • 6. Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models.
    Favre-Guilmard C, Auguet M, Chabrier PE.
    Eur J Pharmacol; 2009 Sep 01; 617(1-3):48-53. PubMed ID: 19576881
    [Abstract] [Full Text] [Related]

  • 7. Botulinum toxin type A reduces histamine-induced itch and vasomotor responses in human skin.
    Gazerani P, Pedersen NS, Drewes AM, Arendt-Nielsen L.
    Br J Dermatol; 2009 Oct 01; 161(4):737-45. PubMed ID: 19624547
    [Abstract] [Full Text] [Related]

  • 8. Intra-articular botulinum toxin A for refractory shoulder pain: a randomized, double-blinded, placebo-controlled trial.
    Singh JA, Mahowald ML, Noorbaloochi S.
    Transl Res; 2009 May 01; 153(5):205-16. PubMed ID: 19375681
    [Abstract] [Full Text] [Related]

  • 9. Botulinum neurotoxin-A for treatment of refractory neck pain: a randomized, double-blind study.
    Miller D, Richardson D, Eisa M, Bajwa RJ, Jabbari B.
    Pain Med; 2009 Sep 01; 10(6):1012-7. PubMed ID: 19594841
    [Abstract] [Full Text] [Related]

  • 10. UV-B irradiation attenuates dermal effects of botulinum toxin A: a randomized, double-blind, placebo-controlled study.
    Sycha T, Kotzailias N, Kranz G, Trautinger F, Schnider P, Auff E.
    Dermatol Surg; 2007 Jan 01; 33(1 Spec No.):S92-6. PubMed ID: 17241421
    [Abstract] [Full Text] [Related]

  • 11. A double-blind, controlled study of botulinum toxin A in chronic myofascial pain.
    Qerama E, Fuglsang-Frederiksen A, Kasch H, Bach FW, Jensen TS.
    Neurology; 2006 Jul 25; 67(2):241-5. PubMed ID: 16864815
    [Abstract] [Full Text] [Related]

  • 12. Anti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain.
    Luvisetto S, Marinelli S, Cobianchi S, Pavone F.
    Neuroscience; 2007 Mar 02; 145(1):1-4. PubMed ID: 17218063
    [Abstract] [Full Text] [Related]

  • 13. Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers.
    Kraft B, Frickey NA, Kaufmann RM, Reif M, Frey R, Gustorff B, Kress HG.
    Anesthesiology; 2008 Jul 02; 109(1):101-10. PubMed ID: 18580179
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study.
    Göbel H, Heinze A, Reichel G, Hefter H, Benecke R, Dysport myofascial pain study group.
    Pain; 2006 Nov 02; 125(1-2):82-8. PubMed ID: 16750294
    [Abstract] [Full Text] [Related]

  • 15. Sudomotor testing predicts the presence of neutralizing botulinum A toxin antibodies.
    Birklein F, Walther D, Bigalke H, Winterholler M, Erbguth F.
    Ann Neurol; 2002 Jul 02; 52(1):68-73. PubMed ID: 12112049
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain.
    Ranoux D, Attal N, Morain F, Bouhassira D.
    Ann Neurol; 2008 Sep 02; 64(3):274-83. PubMed ID: 18546285
    [Abstract] [Full Text] [Related]

  • 18. Brain imaging of analgesic and antihyperalgesic effects of cyclooxygenase inhibition in an experimental human pain model: a functional MRI study.
    Maihöfner C, Ringler R, Herrndobler F, Koppert W.
    Eur J Neurosci; 2007 Sep 02; 26(5):1344-56. PubMed ID: 17767511
    [Abstract] [Full Text] [Related]

  • 19. Antihyperalgesic and analgesic properties of the N-methyl-D-aspartate (NMDA) receptor antagonist neramexane in a human surrogate model of neurogenic hyperalgesia.
    Klein T, Magerl W, Hanschmann A, Althaus M, Treede RD.
    Eur J Pain; 2008 Jan 02; 12(1):17-29. PubMed ID: 17449306
    [Abstract] [Full Text] [Related]

  • 20. Intraprostatic capsaicin injection as a novel model for nonbacterial prostatitis and effects of botulinum toxin A.
    Chuang YC, Yoshimura N, Wu M, Huang CC, Chiang PH, Tyagi P, Chancellor MB.
    Eur Urol; 2007 Apr 02; 51(4):1119-27. PubMed ID: 17141941
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.